Equity Method Income
West Pharmaceutical Services Equity Method Income decreased by 12.8% to $3.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $3.40M to $3.40M. Over 4 years (FY 2021 to FY 2025), Equity Method Income shows a downward trend with a -8.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase reflects strong performance from joint ventures or strategic partners, while a decrease indicates underperformance in those specific investments.
Detailed definition
This metric captures the company's proportionate share of the net earnings or losses from investments in unconsolidated...
Peer comparison
Common in technology and manufacturing sectors where joint ventures are used for R&D or supply chain integration.
equity_method_incomeHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.60M | $6.50M | $0.00 | $7.20M | $5.50M | $4.80M | $3.20M | $5.70M | $5.00M | $3.70M | $3.30M | $4.30M | $4.50M | $3.90M | $2.00M | $3.40M | $5.00M | $2.10M | $3.90M | $3.40M |
| QoQ Change | — | -24.4% | -100.0% | — | -23.6% | -12.7% | -33.3% | +78.1% | -12.3% | -26.0% | -10.8% | +30.3% | +4.7% | -13.3% | -48.7% | +70.0% | +47.1% | -58.0% | +85.7% | -12.8% |
| YoY Change | — | — | — | — | -36.0% | -26.2% | — | -20.8% | -9.1% | -22.9% | +3.1% | -24.6% | -10.0% | +5.4% | -39.4% | -20.9% | +11.1% | -46.2% | +95.0% | +0.0% |
Equity Method Income at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's equity method income?
- West Pharmaceutical Services (WST) reported equity method income of $3.40M in Q1 2026.
- How has West Pharmaceutical Services's equity method income changed year-over-year?
- West Pharmaceutical Services's equity method income decreased by 0.0% year-over-year, from $3.40M to $3.40M.
- What is the long-term trend for West Pharmaceutical Services's equity method income?
- Over 4 years (2021 to 2025), West Pharmaceutical Services's equity method income has grown at a -8.0% compound annual growth rate (CAGR), from $20.10M to $14.40M.
- What does equity method income mean?
- The company's share of profits or losses from businesses it partially owns.